Kangshino MRNA vaccine enters the trial production stage of the design capacity of 100

The first messenger ribonucleic acid (MRNA) coronary vaccine developed by Chinese Pharmaceuticals Kangshino Biological Co., Ltd. has entered the trial production stage and has a design capacity of 100 million doses.One of the vaccines.

Kangshino issued an announcement on the evening of the 5th of this month to disclose the latest progress of the CS-20134 jointly developed by Kangshino and its subordinates.The announcement states that the MRNA vaccine CS-20134 production capacity of the MRNA vaccine developed for Omikon poisonous strains was 100 million doses of production capacity.

Announcement stated that CS-2034 has obtained positive staged data in a clinical study that enhances safety and immunogenicity.

This clinical study was launched in October last year.The results of the research show that one dose CS-2034 is strengthened among people who have been vaccinated in the past.The MRNA vaccine has been listed, and the safety of the sub -group of the elderly is better than the adult sub -group.

In terms of immunogenicity, the test results of the neutral and antibody detection of real viruses show that 28 days after CS-2034 strengthened, the neutral antibodies of prototypes and Omikon BA.1 mutant strains were extinguished, respectively.27 and 23 times that of living vaccines have been enhanced.

Kangshino said that as of now, CS-2034 is still in the clinical IIB stage, and the current progress is in line with expectations.At the same time, the "3+1" sequence of this vaccine strengthening clinical research is also under development.In terms of production capacity construction, the first phase of the production base of Shanghai Lingang has a design capacity of 100 million doses. It has begun to verify and entered the trial production stage.

For the outbreak of the epidemic, China has mainly relied on domestic vaccines that use the use of activated technologies, but these vaccines are not enough to prevent the spread of coronal virus.In September last year, China approved the inhaled vaccine produced by Kangxino for enhanced needles. This is the first inhaling crown vaccine launched in the world.In November of the same year, China agreed to approve Pfizer's MRNA vaccine in China, but only faced some foreign residents.

At present, after China's significant relaxation of domestic epidemic control measures, it is facing the biggest trend of infection since the outbreak of the epidemic.

Three sources told Reuters that China is actively negotiating with Pfizer's production and distribution permit for the production and distribution of a crown disease.Beijing hopes to finalize this license clause before January 22.January 22 is the first day of the first month of the Lunar New Year.